Is lipoprotein(a) an inherited cardiovascular risk factor even when LDL cholesterol is optimal?

Lipoprotein(a) [Lp(a)] is an independent, highly heritable lipid fraction that serves as a critical marker for residual cardiovascular risk, even when standard lipid panels appear optimal.

Genetic determination and metabolic independence

• Strong genetic control: Between 70% and 95% of the variance in plasma Lp(a) levels is genetically determined by the LPA gene locus. The primary driver is the Kringle IV type 2 (KIV-2) copy-number variation, where fewer repeats lead to higher plasma concentrations. Dietary and lifestyle factors exert minimal influence (accounting for only 5% to 30% of variance).
• Independence from LDL-C: Lp(a) levels fluctuate independently of standard LDL-C (correlation coefficient $r \approx 0.05$ to $0.20$) due to distinct biosynthetic and clearance pathways. Standard lipid-lowering therapies like statins upregulate LDL receptors but fail to reduce Lp(a) levels, occasionally even causing minor increases.

Inherited atherogenic particle burden

• Additive particle count: Every Lp(a) particle contains exactly one apolipoprotein B-100 (ApoB) molecule. Consequently, elevated Lp(a) directly increases the total circulating atherogenic particle burden (measured via ApoB and LDL-P), even in individuals with optimal LDL-C carrier mass.
• Causal cardiovascular risk: Mendelian randomization and cohort studies confirm that elevated Lp(a) causally increases the risk of coronary heart disease and atherosclerotic cardiovascular disease. For example, data from the Multi-Ethnic Study of Atherosclerosis (MESA) show that individuals with optimal LDL-C ($\le 100\text{ mg/dL}$) but elevated Lp(a) ($\ge 50\text{ mg/dL}$) experience a significant increase in coronary heart disease risk (HR 1.83).

Bottom line

• Lipoprotein(a) is a genetically determined, independent driver of cardiovascular risk. Because each Lp(a) particle carries an ApoB molecule, elevated levels create a silent, inherited atherogenic particle burden that persists and drives residual risk even when standard LDL-C levels are optimal.